Cetera Advisors’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,417
| Closed | -$27K | – | 1477 |
|
|
2022
Q1 | $27K | Sell |
1,417
-100
| -7% | -$1.57K | ﹤0.01% | 1380 |
|
|
2021
Q4 | $27K | Sell |
1,517
-809
| -35% | -$24.2K | ﹤0.01% | 1413 |
|
|
2021
Q3 | $86K | Buy |
2,326
+769
| +49% | +$34.1K | ﹤0.01% | 1358 |
|
|
2021
Q2 | $93K | Sell |
1,557
-32
| -2% | -$1.94K | ﹤0.01% | 1291 |
|
|
2021
Q1 | $106K | Buy |
1,589
+79
| +5% | +$6.18K | ﹤0.01% | 1184 |
|
|
2020
Q4 | $91K | Buy |
1,510
+32
| +2% | +$2.19K | ﹤0.01% | 1015 |
|
|
2020
Q3 | $117K | Sell |
1,478
-380
| -20% | -$30.3K | ﹤0.01% | 916 |
|
|
2020
Q2 | $116K | Buy |
1,858
+65
| +4% | +$3.78K | ﹤0.01% | 873 |
|
|
2020
Q1 | $95K | Sell |
1,793
-319
| -15% | -$31.6K | 0.01% | 762 |
|
|
2019
Q4 | $250K | Buy |
2,112
+12
| +0.6% | +$1.73K | 0.01% | 785 |
|
|
2019
Q3 | $384K | Buy |
2,100
+209
| +11% | +$29.5K | 0.02% | 622 |
|
|
2019
Q2 | $251K | Buy |
1,891
+336
| +22% | +$60.2K | 0.01% | 771 |
|
|
2019
Q1 | $380K | Buy |
1,555
+189
| +14% | +$50K | 0.02% | 575 |
|
|
2018
Q4 | $265K | Sell |
1,366
-110
| -7% | -$26.8K | 0.02% | 671 |
|
|
2018
Q3 | $488K | Buy |
1,476
+432
| +41% | +$132K | 0.02% | 576 |
|
|
2018
Q2 | $322K | Sell |
1,044
-105
| -9% | -$32.1K | 0.02% | 642 |
|
|
2018
Q1 | $281K | Buy |
1,149
+176
| +18% | +$49.4K | 0.02% | 632 |
|
|
2017
Q4 | $294K | Buy |
973
+119
| +14% | +$33.1K | 0.02% | 584 |
|
|
2017
Q3 | $225K | Buy |
854
+38
| +5% | +$11K | 0.01% | 713 |
|
|
2017
Q2 | $214K | Buy |
816
+60
| +8% | +$15K | 0.01% | 711 |
|
|
2017
Q1 | $272K | Buy |
756
+61
| +9% | +$18.9K | 0.02% | 608 |
|
|
2016
Q4 | $202K | Hold |
695
| – | – | 0.02% | 643 |
|
|
2016
Q3 | $237K | Sell |
695
-240
| -26% | -$87.7K | 0.02% | 618 |
|
|
2016
Q2 | $400K | Sell |
935
-211
| -18% | -$87K | 0.03% | 485 |
|
|
2016
Q1 | $367K | Buy |
1,146
+40
| +4% | +$13.6K | 0.03% | 476 |
|
|
2015
Q4 | $573K | Buy |
1,106
+25
| +2% | +$9.23K | 0.05% | 371 |
|
|
2015
Q3 | $316K | Buy |
1,081
+40
| +4% | +$14.2K | 0.03% | 477 |
|
|
2015
Q2 | $409K | Buy |
1,041
+25
| +2% | +$8.82K | 0.03% | 429 |
|
|
2015
Q1 | $308K | Hold |
1,016
| – | – | 0.03% | 494 |
|
|
2014
Q4 | $225K | Buy |
1,016
+20
| +2% | +$4.13K | 0.02% | 567 |
|
|
2014
Q3 | $232K | Buy |
996
+40
| +4% | +$10.1K | 0.02% | 510 |
|
|
2014
Q2 | $211K | Buy |
956
+230
| +32% | +$51.2K | 0.02% | 533 |
|
|
2014
Q1 | $228K | Hold |
726
| – | – | 0.03% | 452 |
|
|
2013
Q4 | $189K | Buy |
726
+246
| +51% | +$53.9K | 0.03% | 467 |
|
|
2013
Q3 | $70K | Sell |
480
-70
| -13% | -$8.46K | 0.01% | 437 |
|
|
2013
Q2 | $83K | Buy |
+550
| New | +$75.3K | 0.02% | 377 |
|
Other funds holding TXMD
RCMNY
E
GF
Cetera Advisors's TXMD Position: Q2 2022 in Review
Cetera Advisors sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 1,417 shares — an estimated $27K sold.
Cetera Advisors first reported a position in TXMD in Q2 2013 and held it in 36 quarters. The position peaked at $573K in Q4 2015. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.
- Cetera Advisors reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
- Cetera Advisors sold 1,417 TherapeuticsMD shares in Q2 2022, an estimated $27K.
- Cetera Advisors first reported a position in TherapeuticsMD in Q2 2013 and held it in 36 quarters.
- Cetera Advisors's TherapeuticsMD position peaked at $573K in Q4 2015.
- 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.
Based on Cetera Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.